variou
way
new
drug
develop
one
approach
silico
drug
design
base
exist
knowledg
biolog
specif
diseas
specif
target
site
bind
chemistri
base
knowledg
rang
molecul
design
synthesis
test
vitro
bioassay
activ
toxic
best
candid
call
lead
compound
finetun
chemic
derivatis
order
improv
activ
andor
reduc
toxic
lead
compound
test
variou
anim
model
enter
clinic
trial
peopl
anoth
approach
screen
larg
number
biolog
sampl
plant
bacteria
fungi
activ
specif
diseas
activ
extract
consist
mani
compound
fraction
chromatograph
techniqu
fraction
test
vitro
activ
activ
fraction
fraction
activ
compound
identifi
process
also
call
bioguid
fraction
go
number
fraction
cycl
activ
compound
identifi
activ
compound
chemic
derivatis
order
improv
properti
vivo
anim
studi
conduct
base
test
result
promis
lead
compound
test
clinic
trial
peopl
howev
number
shortcom
approach
expens
time
consum
make
use
vitro
bioassay
suffer
low
success
rate
due
shortcom
current
estim
develop
one
new
drug
cost
around
billion
simpli
mani
lead
compound
fail
clinic
trial
keep
high
cost
mind
one
would
think
regist
drug
effect
importantli
nontox
unfortun
case
number
drug
current
market
caus
sever
side
effect
whose
efficaci
question
hold
true
particularli
cancer
chemotherapeut
estim
cancer
chemotherapi
improv
averag
surviv
rate
patient
cancer
type
morgan
et
al
anoth
rel
unknown
fact
year
peopl
die
eu
due
advers
drug
reaction
type
drug
highlight
sever
shortcom
drug
develop
drug
licens
pipelin
archibald
coleman
put
perspect
larg
number
drug
work
perfectli
well
safe
use
conced
approach
drug
discoveri
overal
approach
health
care
suffer
major
problem
altern
approach
problem
partli
sidestep
one
approach
call
revers
pharmacolog
rel
simpl
approach
identifi
tradit
medicin
eg
predominantli
medicin
plant
known
nontox
vivo
extrem
import
aspect
lead
compound
identifi
normal
drug
discoveri
process
fail
clinic
trial
due
vivo
toxic
identifi
medicin
plant
use
still
use
thousand
peopl
without
report
toxic
practic
sidestep
major
problem
second
step
revers
pharmacolog
work
way
back
activ
compound
use
vitro
bioassay
therefor
start
vivo
uncontrol
clinic
trial
follow
vitro
identif
activ
compound
one
notabl
differ
normal
drug
discoveri
process
system
necessarili
need
vivo
anim
studi
conduct
howev
drug
registr
author
demand
anim
studi
conduct
registr
revers
pharmacolog
approach
howev
without
shortcom
either
main
problem
vitro
bioassay
use
lead
set
problem
experienc
normal
drug
discoveri
pipelin
stage
process
main
problem
vitro
bioassay
follow
exclud
influenc
human
metabol
activ
compound
therefor
detect
socal
prodrug
prodrug
compound
inact
natur
form
chemic
alter
normal
metabol
becom
activ
bioassay
design
identifi
compound
specif
mechan
action
instanc
consist
singl
enzym
eg
hiv
integras
specif
life
cycl
stage
parasit
activ
compound
bind
enzym
act
specif
life
cycl
stage
might
therefor
deem
inactivea
socal
fals
neg
bioassay
test
import
pharmacokinet
dynam
aspect
bioavail
compound
bioavail
vivo
vitro
activ
matter
much
bioavail
howev
improv
encapsul
techniqu
bioassay
normal
make
use
foreign
organ
chemic
media
react
therebi
deactiv
activ
compound
lead
larg
number
fals
neg
common
compound
found
mani
plant
also
react
bioassay
media
constitu
make
activ
lead
larg
number
fals
posit
main
issu
howev
problem
fals
posit
fals
neg
fals
posit
compound
deem
activ
specif
bioassay
larg
amount
time
effort
spent
identif
fortun
fals
posit
eventu
alway
reveal
unfortun
cost
time
fund
fals
neg
far
seriou
problem
react
specif
enzym
bioassay
use
therefor
deem
inact
may
even
degrad
foreign
media
use
bioassay
main
problem
fals
neg
never
reveal
exampl
publish
medicin
plant
x
show
activ
diseas
x
peopl
go
reinvestig
unfortun
problem
also
import
use
vitro
bioassay
test
toxic
lead
compound
activ
extract
find
occurr
fals
posit
neg
fals
posit
compound
react
specif
cell
lead
cell
death
conclus
made
compound
extract
toxic
good
exampl
recent
test
english
tea
camellia
sinensi
neg
control
specif
cell
line
due
toxic
specif
cell
line
experi
could
continu
could
use
normal
tea
neg
control
unpublish
result
mani
million
peopl
drink
tea
everi
day
without
shortor
longterm
toxic
report
thu
far
put
perspect
medicin
plant
would
conclud
far
toxic
would
continu
investig
fals
neg
toxic
bioassay
speak
countless
exampl
lead
compound
deem
safe
vitro
even
vivo
anim
studi
turn
toxic
peopl
mani
problem
associ
vitro
bioassay
remain
problem
normal
drug
discoveri
pipelin
well
revers
pharmacolog
approach
advic
interpret
vitro
result
care
two
approach
drug
discoveri
call
normal
revers
approach
unfortun
moment
exclus
main
reason
scientif
econom
polit
aspect
shortli
discuss
live
segreg
world
one
side
rich
western
countri
unsustain
complex
econom
system
capit
side
poorer
nonwestern
countri
sustain
simpler
econom
system
western
countri
scientif
research
lead
creation
financi
profit
short
term
order
sustain
complex
econom
system
practic
mean
fund
research
new
medicin
made
avail
research
lead
develop
new
drug
sold
profit
order
creat
sustain
compani
keep
peopl
employ
short
keep
economi
grow
profit
need
made
noth
wrong
approach
howev
focu
creation
wealth
employ
short
term
health
peopl
one
advantag
econom
system
scientif
level
countri
extrem
wellequip
laboratori
perform
indepth
scientif
research
new
medicin
long
potenti
profit
take
centr
stage
research
medicin
plant
basic
stop
simpl
reason
medicin
plant
produc
sold
order
creat
wealthit
inexpens
therefor
abl
financi
sustain
anyon
compani
identifi
new
lead
compound
medicin
plant
support
degre
possibl
patent
eventu
profit
exist
harsh
realiti
medicin
plant
work
scienc
behind
realli
matter
allit
fit
econom
model
nonwestern
countri
focu
still
primarili
health
peopl
shortterm
direct
profit
medicin
plant
alway
play
role
continu
long
main
object
health
citizen
direct
shortterm
profit
peopl
sell
medicin
plant
profit
countri
cours
take
place
compar
scale
cost
drug
western
countri
possibl
reconcil
two
world
research
medicin
plant
take
place
western
countri
order
use
way
see
choic
anymor
health
care
system
mani
western
countri
verg
collaps
appear
capitalist
model
health
care
good
mix
fast
grow
lack
trust
extrem
high
cost
involv
probabl
main
reason
becom
expens
proven
fact
mani
peopl
western
countri
alreadi
exclud
primari
health
care
simpli
afford
find
way
reduc
cost
health
care
western
countri
expens
medicin
cours
one
part
overal
cost
health
care
system
good
start
point
need
done
studi
health
care
system
nonwestern
countri
appli
vast
resourc
western
countri
studi
specif
type
medicin
use
order
provid
creat
evidencebas
qualitycontrol
inexpens
effect
medicin
clear
tradit
medicin
use
nonwestern
countri
work
mani
failur
might
also
big
success
one
medicin
plant
studi
detail
artemisia
annua
l
asteracea
fig
medicin
plant
potenti
satisfi
current
need
world
also
potenti
bring
two
world
closer
togeth
yield
singl
compound
develop
drugwhich
alreadi
also
use
form
medicin
plant
inexpens
effect
treatment
lifethreaten
diseas
nonwestern
countrieswhich
alreadi
sincer
hope
plant
one
day
even
use
western
countri
soon
scientif
evid
efficaci
provid
need
indepth
scientif
research
moment
unfortun
support
western
countri
due
aforement
econom
reason
address
recent
publish
review
paper
deal
scientif
complex
face
studi
plant
recommend
logic
next
step
taken
van
der
kooy
sullivan
chapter
therefor
describ
anoth
import
aspect
annua
fig
discoveri
remark
antihiv
activ
plant
give
short
introduct
histori
annua
biolog
activ
associ
plant
report
antivir
activ
specif
antihiv
activ
compound
identifi
tradit
prepar
annua
formul
potenti
impact
discoveri
need
continu
research
also
discuss
annua
use
hundr
year
treat
variou
ailment
specif
relat
treatment
intermitt
fever
tradit
use
link
malari
infect
caus
plasmodium
falciparum
parasit
annua
one
activ
compound
sesquiterpen
lacton
endoperoxid
call
artemisinin
identifi
current
use
artemisinin
deriv
firstlin
treatment
malaria
de
ridder
et
al
tradit
use
annua
form
tea
infus
prepar
dri
leav
foreground
artemisia
annua
plant
background
user
plant
tea
infus
treatment
variou
diseas
photo
permiss
anam
continu
use
china
due
appar
effect
rapidli
spread
across
globe
recent
time
current
use
world
inexpens
treatment
malaria
oppos
whorecommend
artemisinin
deriv
tradit
use
annua
caus
larg
amount
controversi
fear
resist
artemisinin
might
develop
tradit
use
plant
howev
oppos
view
state
annua
use
hundr
year
without
resist
develop
sinc
singl
compound
plant
use
resist
develop
use
annua
howev
import
implic
specif
antimalari
treatment
develop
countri
high
cost
commerci
drug
make
practic
inaccess
mani
also
import
implic
western
countri
gener
high
cost
health
care
alreadi
exclud
mani
receiv
adequ
treatment
diseas
common
view
use
annua
support
rel
simplist
order
reach
prescrib
dose
main
activ
compound
artemisinin
conclud
artemisinin
combin
therapi
act
way
approach
treatment
malaria
mueller
et
al
clash
westernbas
drug
eg
artemisinin
tradit
medicin
medicin
plant
eg
annua
culmin
public
posit
statement
use
annua
treatment
malaria
main
recommend
statement
use
annua
form
includ
tea
infus
due
low
natur
abund
artemisinin
annua
liu
et
al
full
discuss
tradit
use
annua
hsu
consult
full
discuss
controversi
surround
use
annua
versu
whorecommend
use
artemisinin
deriv
van
der
kooy
sullivan
consult
howev
problem
relat
use
artemisinin
main
problem
fastact
drug
short
halflif
therefor
need
combin
sloweract
drug
order
assur
effect
elimin
parasitaemia
anoth
problem
assur
adequ
suppli
artemisinin
due
complex
chemic
structur
synthesi
andor
semisynthesi
remain
difficult
therefor
main
sourc
artemisinin
remain
isol
purif
annua
plant
due
environment
econom
influenc
annual
product
annua
suffer
boom
bust
cycl
overproduct
low
price
one
year
underproduct
high
price
next
year
cost
westernstyl
treatment
also
far
high
usedpredominantli
nonwestern
countri
order
stabilis
global
product
annua
price
artemisinin
variou
approach
taken
increas
yield
artemisinin
annua
classic
plant
breed
techniqu
employ
bartlet
isol
purif
techniqu
continu
improv
liu
et
al
chemic
synthesi
artemisinin
success
degre
dietrich
et
al
note
research
taken
place
western
countri
focu
singl
compound
artemisinin
anoth
novel
approach
would
identifi
second
activ
pharmaceut
ingredi
api
order
reduc
overal
product
cost
artemisinin
lubb
et
al
order
tradit
current
use
annua
diseas
malaria
investig
antihiv
activ
artemisia
annua
annua
current
mainli
use
treatment
malaria
also
treatment
skin
digest
ailment
hivaid
bronchiti
cancer
haemorrhoid
altern
use
medicin
plant
recommend
ngo
ifbvbelherb
anam
section
howev
deal
antivir
activ
associ
artemisia
spp
artemisinin
report
artemisia
speci
show
antihiv
activ
limit
caruifolia
capillari
et
al
identifi
four
compound
methanol
extract
caruifolia
name
deriv
show
around
inhibit
proteas
concentr
lgml
three
dicaffeoylquin
acid
deriv
also
isol
studi
show
appreci
activ
proteas
howev
co
et
al
report
acid
inde
show
good
activ
hiv
integras
although
controversi
remain
around
potenc
activ
vivo
metabolom
investig
annua
afra
coumaroylspermidin
deriv
detect
either
speci
test
liu
et
al
report
could
found
compound
identifi
annua
wu
et
al
conclud
activ
antihiv
compon
present
capilari
flavonoid
isorhamnetin
arcapillin
well
coumarin
deriv
aesculetin
annua
shown
possess
wide
varieti
antivir
effect
notabl
herp
simplex
viru
type
karamoddini
conduct
vitro
test
methanol
extract
homogenis
plant
materi
variou
artemisia
speci
annua
show
highest
antiherpet
activ
annua
also
test
common
antivir
drug
acyclovir
show
higher
activ
commerci
drug
karamoddini
possibl
note
antiherpet
effect
could
caus
artemisinin
howev
synerg
activ
compound
yet
test
relat
annua
shown
activ
sever
acut
respiratori
syndromeassoci
coronaviru
highli
deadli
contagi
diseas
li
et
al
li
et
al
test
ethanol
extract
annua
three
plant
speci
viru
determin
annua
ec
lgml
abid
ali
khan
et
al
studi
antivir
activ
annua
tobamovirus
plant
sampl
extract
nhexan
evalu
tobamoviru
viru
cultur
inhibit
note
abid
ali
khan
et
al
fraction
extract
collect
activ
fraction
determin
activ
compound
sterol
outcom
studi
import
note
artemisinin
identifi
viru
inhibitor
pure
compound
artemisinin
also
show
signific
activ
toward
bovin
viral
diarrhoea
viru
bvdv
romero
et
al
bvdv
class
pestiviru
flavivirida
famili
studi
bovin
epitheli
cell
infect
bvdv
viru
treat
artemisinin
found
artemisinin
inhibitor
flavivirida
virus
possibl
applic
treatment
hepat
c
viru
hcv
hcv
similar
hiv
rna
virus
howev
hiv
retroviru
integr
host
dna
paeshuys
et
al
confirm
test
artemisinin
hcv
found
activ
level
lm
activ
potenti
hemin
concentr
effect
host
cell
indic
pronounc
synergist
antivir
activ
artemisinin
hemin
combin
understand
annua
extract
artemisinin
interact
inhibit
virus
could
enabl
futur
investig
discov
develop
practic
inexpens
treatment
virus
similar
natur
like
hiv
romero
et
al
studi
activ
artemisinin
hepat
b
viru
hbv
note
ic
valu
lm
inhibit
hepat
b
envelop
protein
surfac
antigen
hbvdna
releas
respect
interestingli
artemisinin
prove
effect
antivir
commonli
use
deriv
artesun
ic
valu
lm
respect
vivo
activ
survey
complet
willcox
et
al
kenya
uganda
report
n
respond
use
annua
infus
diseas
malaria
n
use
infus
treatment
hiv
furthermor
survey
complet
noumi
manga
cameroon
also
note
respond
use
annua
relat
hivaid
aburaddad
et
al
hypothesis
spread
malaria
parasit
may
enabl
spread
hiv
viru
throughout
africa
due
taint
blood
use
transfus
hypothesi
give
reason
studi
current
malaria
treatment
relat
hiv
like
annua
commonli
use
medicin
plant
vitro
activ
inform
regard
vitro
antihiv
activ
annua
artemisinin
rather
limit
chang
woo
test
methanol
extract
commonli
use
korean
medicin
plant
hiv
relat
viruscel
fusion
inhibit
use
syncytium
inhibit
assay
base
interact
envelop
cellular
membran
protein
tlymphocyt
inhibit
seen
concentr
test
even
though
rel
low
compar
plant
test
seri
therefor
solvent
extract
fraction
annua
test
studi
realiti
organ
extract
use
rather
tea
infus
brew
administ
variou
patent
exist
cover
broad
biolog
activ
includ
antivir
activ
annua
combin
medicin
herb
zhang
zhang
chen
nagaura
xue
b
zhang
chen
first
report
artemisinin
deriv
use
antihiv
agent
publish
jung
schinazi
embark
studi
artemisinin
trioxan
deriv
conclud
antihiv
activ
common
artemisinin
trioxan
deriv
given
result
evalu
need
potenti
antihiv
treatment
produc
lubb
et
al
investig
tradit
infus
annua
afra
compar
pure
artemisinin
relat
antihiv
activ
note
infus
exhibit
potent
inhibit
annua
ic
lgml
wherea
pure
artemisinin
show
inhibit
even
lgml
artemisia
afra
contain
artemisinin
show
similar
level
activ
hiv
indic
activ
compound
probabl
artemisinin
given
survey
complet
willcox
et
al
noumi
manga
clear
relationship
plant
disord
seen
implement
revers
pharmacolog
case
like
would
enabl
research
possibl
develop
effect
treatment
variou
virus
specif
hiv
diseas
given
sociohistor
valid
keep
mind
econom
polit
aspect
surround
discoveri
develop
new
drug
embark
nonfund
project
order
studi
possibl
reduc
price
accompani
price
fluctuat
artemisinin
identifi
second
api
annua
revers
pharmacolog
approach
taken
mean
find
evid
annua
use
thousand
peopl
without
report
toxic
mani
part
world
specif
nonwestern
countri
peopl
reli
tradit
medicin
primari
sourc
health
care
need
farnsworth
rel
new
diseas
hiv
identif
medicin
plant
work
new
diseas
therefor
still
undergo
process
trial
error
nevertheless
smallscal
survey
conduct
wilcox
et
al
noumi
manga
reveal
hivinfect
patient
start
use
annua
infus
treatment
hiv
although
origin
treatment
intend
malaria
survey
patient
prepar
tea
infus
annua
either
alon
plant
speci
feedback
nongovernment
organis
anam
also
claim
herb
often
use
hiv
patient
inform
import
know
annua
use
thousand
peopl
treatment
malaria
without
toxic
report
thu
far
effect
larg
uncontrol
clinic
trial
conduct
exactli
take
place
highest
burden
hiv
occur
given
us
two
import
outcom
annua
tea
infus
appear
nontox
exhibit
claim
vivo
antihiv
activ
first
import
step
toxic
biggest
problem
experienc
drug
discoveri
process
next
step
revers
pharmacolog
provid
vitro
evid
tradit
tea
infus
inde
activ
hiv
two
question
need
answer
annua
tea
infus
exhibit
vitro
antihiv
activ
activ
caus
artemisinin
order
test
artemisinin
respons
report
vivo
antihiv
activ
therefor
includ
chemic
similar
plant
contain
artemisinin
previou
work
conduct
artemisia
afra
jacq
ex
wild
asteracea
reveal
chemic
similar
annua
importantli
contain
artemisinin
liu
et
al
van
der
kooy
et
al
inclus
afra
done
order
determin
whether
artemisinin
respons
observ
antihiv
activ
whether
combin
artemisinin
compon
explain
observ
activ
synerg
furthermor
could
find
literatur
report
afra
test
hiv
liu
et
al
except
one
report
hivinfect
patient
given
afra
togeth
standard
hiv
treatment
order
boost
immun
system
mulholland
drew
prepar
tea
infus
nine
annua
one
afra
sampl
accord
van
der
kooy
verpoort
test
hiv
accord
lubb
et
al
plant
materi
collect
differ
part
world
differ
year
result
indic
annua
tea
infus
ic
valu
lgml
afra
infus
ic
valu
lgml
valu
correct
variat
posit
control
lubb
et
al
tabl
result
quit
remark
co
et
al
report
singl
compound
activ
lgml
consid
signific
antivir
activ
know
tea
infus
prepar
annua
consist
mani
compound
mouton
et
al
make
chemic
complex
extract
highli
activ
hiv
furthermor
activ
sampl
appear
rel
similar
indic
concentr
activ
compound
sampl
probabl
similar
furthermor
activ
compound
appear
stabl
number
year
oldest
plant
sampl
test
year
old
result
answer
first
question
annua
tea
infus
inde
exhibit
good
vitro
activ
hiv
care
interpret
result
keep
mind
vitro
bioassay
suffer
sever
shortcom
discuss
introduct
chapter
possibl
exist
result
noth
fals
posit
unfortun
time
tell
anoth
possibl
explan
antihiv
activ
synerg
artemisinin
compound
extract
inclus
afra
contain
artemisinin
observ
activ
sampl
appear
artemisinin
limit
role
play
shown
liu
et
al
two
speci
chemic
close
relat
major
except
artemisinin
yet
detect
afra
specimen
also
one
first
report
afra
possess
signific
vitro
antihiv
activ
lubb
et
al
provid
scientif
evid
report
mulholland
drew
patient
given
afra
combin
standard
hiv
treatment
report
improv
symptom
compar
patient
take
standard
hiv
treatment
artemisia
afra
might
therefor
boost
immun
system
may
also
direct
activ
hiv
first
step
revers
pharmacolog
approach
rel
simpl
identifi
medicin
plant
use
thousand
peopl
around
world
without
report
toxic
second
step
somewhat
difficult
use
vitro
bioassay
order
identifi
compound
respons
activ
stand
yet
know
compound
annua
afra
respons
observ
vitro
antihiv
activ
due
reason
discuss
introduct
research
chemistri
annua
tea
infus
support
western
countri
therefor
interest
note
littl
chemic
work
done
tradit
tea
infus
prepar
plant
due
limit
data
report
current
known
identifi
compound
annua
tea
infus
regard
possibl
antihiv
activ
limit
amount
chemic
studi
perform
annua
tea
infus
studi
also
focuss
extract
quantif
artemisinin
without
conduct
complet
chemic
profil
annua
formul
base
limit
data
main
conclus
drawn
tea
infus
ineffect
use
mueller
et
al
mueller
et
al
rath
et
al
jansen
van
der
kooy
sullivan
view
unfortun
simplist
take
closer
look
tradit
medicin
realis
chemistri
tradit
formul
consist
two
part
chemistri
medicin
plant
chemic
influenc
prepar
method
final
formul
first
aspect
studi
detail
year
secondari
metabolit
identifi
report
annua
brown
contrast
compound
identifi
tea
infus
cold
water
extract
mainli
consist
caffeic
acid
deriv
flavonoid
coumarin
artemisinin
van
der
kooy
sullivan
influenc
prepar
method
chemistri
final
formul
studi
put
perspect
know
raw
potato
tast
differ
cook
potato
indic
prepar
method
chang
chemistri
effect
prepar
method
chemistri
final
formul
annua
tea
infus
chemic
chang
occur
due
high
temperatur
involv
also
due
water
chemistri
field
condit
peopl
use
water
avail
prepar
tea
infus
know
water
contain
larg
variabl
amount
salt
element
salt
element
react
organ
molecul
extract
annua
implic
discuss
van
der
kooy
sullivan
chemic
chang
possibl
larg
effect
overal
activ
tea
infus
also
clearli
state
potenti
opposit
effect
wellth
infus
might
becom
less
effect
lab
recent
identifi
two
new
compound
tea
infus
cisand
transmelilotosid
first
report
compound
artemisia
spp
mouton
et
al
figur
illustr
chemic
structur
compound
identifi
annua
tea
infus
due
limit
chemic
data
yet
know
compound
annua
tea
infus
respons
antihiv
activ
possibl
might
one
compound
alreadi
identifi
discuss
keep
mind
use
vitro
bioassay
exclud
prodrug
identifi
compound
whose
mechan
action
differ
target
bioassay
section
describ
current
known
antihiv
activ
identifi
compound
date
chlorogen
acid
deriv
group
compound
wide
distribut
plant
kingdom
fact
also
make
biolog
activ
especi
antihiv
activ
controversi
almost
plant
contain
chlorogen
acid
deriv
would
therefor
odd
compound
also
main
activ
constitu
mayb
proof
eat
indic
good
balanc
diet
consist
fruit
veget
fend
diseas
nevertheless
class
compound
thought
exhibit
good
antihiv
activ
patent
cover
use
antihiv
treatment
hard
et
al
sun
et
al
co
et
al
also
report
acid
inde
show
good
activ
hiv
integras
although
controversi
remain
around
potenc
activ
vivo
howev
latest
find
base
posit
report
african
commun
use
annua
tea
infus
treatment
hiv
indic
inde
strong
antihiv
activ
annua
tea
infus
lubb
et
al
activ
therefor
partli
ascrib
chlorogen
acid
class
compound
coumarin
coumarin
identifi
annua
tea
infus
test
wu
et
al
hiv
found
inact
coumarin
howev
known
anticoagul
properti
warfarin
best
exampl
possibl
influenc
blood
coagul
properti
may
indirect
effect
antihiv
compound
although
remain
shown
melilotosid
rel
rare
compound
show
good
activ
diarrhoeacaus
pathogen
entamoeba
histolytica
giardia
lamblia
ic
lgml
respect
indic
tradit
use
annua
treatment
diarrhoea
might
effect
calzada
et
al
report
could
found
activ
hiv
although
compound
hydrolys
respect
ocoumar
acid
digest
tract
ocoumar
acid
yet
test
hiv
zhuang
et
al
report
exhibit
activ
sar
viru
flavonoid
vitexin
chrysoeriol
cirsilineol
test
wu
et
al
hiv
replic
found
inact
piccinelli
et
al
also
test
vitixin
isovitixin
hiv
report
weak
activ
patuletin
glycosid
yet
studi
hiv
rutin
test
leehuang
et
al
found
inact
jaceidin
chrysosplenol
chrysosplenetin
also
yet
test
hiv
none
flavonoid
identifi
thu
far
annua
tea
infus
show
strong
activ
hiv
vitro
hiv
bioassay
use
keep
mind
vitro
bioassay
exclud
identif
prodrug
put
perspect
tao
et
al
report
strong
antihiv
activ
sodiumrutinsulph
complex
highlight
possibl
salt
element
water
activ
common
compound
might
otherwis
inact
terpenoid
artemisinin
test
variou
virus
efferth
report
broad
antivir
activ
artemisinin
semisynthet
deriv
artesun
artesun
show
inhibit
hiv
level
nm
report
activ
artemisinin
hiv
given
jung
schinazi
report
antihiv
activ
artemisinin
ec
ic
greater
lm
benedikt
et
al
patent
artemisinin
deriv
variou
virus
patent
descript
activ
artemisinin
given
insignific
lubb
et
al
found
artemisinin
inact
hiv
concentr
lgml
therefor
conflict
report
activ
artemisinin
hiv
probabl
caus
differ
bioassay
use
discuss
avail
literatur
associ
identifi
compound
conclud
remain
unclear
compound
respons
observ
vitro
activ
claim
vivo
activ
chlorogen
acid
famili
potenti
role
play
observ
activ
coumarin
appear
direct
role
play
melilotosid
yet
test
flavonoid
test
show
high
level
activ
hiv
concentr
flavonoid
tea
infus
also
found
rather
low
furthermor
decreas
possibl
class
compound
respons
activ
flavonoid
role
play
form
prodrug
tao
et
al
report
strong
antihiv
activ
sodiumrutinsulph
complex
artemisinin
test
hiv
use
variou
bioassay
report
activ
somewhat
contradictori
therefor
appear
none
compound
identifi
thu
far
seen
main
antihiv
compound
logic
next
step
take
would
perform
full
chemic
investig
tea
infus
includ
chemic
reaction
take
place
prepar
tea
variou
chemic
present
water
also
import
vitro
antihiv
activ
tea
infus
confirm
independ
laboratori
order
decreas
possibl
result
might
fals
posit
activ
confirm
activ
compound
identifi
normal
bioguid
fraction
process
keep
mind
fraction
lead
loss
activ
effect
combin
difficulti
face
vitro
bioassay
make
task
difficult
appear
schmidt
et
al
wagner
ulrichmerzenich
gertsch
give
us
potenti
lead
narrow
possibl
take
revers
approach
look
chemic
structur
exist
hiv
drug
current
develop
use
similar
structur
compound
identifi
annua
tea
infus
one
hiv
drug
bevirimat
base
structur
betulin
acid
triterpenoid
asteracea
famili
plant
known
contain
wide
varieti
terpenoid
variou
biolog
activ
associ
group
compound
annua
report
contain
oleanol
acid
tritepenoid
structur
similar
bevirimat
yet
none
compound
identifi
tea
infus
appear
focuss
identif
terpenoid
tea
infus
might
good
start
point
chapter
highlight
aspect
regard
drug
discoveri
process
sever
shortcom
current
approach
chapter
annua
rather
use
medicin
plant
exampl
illustr
rather
philosoph
aspect
approach
gener
health
care
system
western
countri
revers
pharmacolog
approach
inde
hold
key
faster
inexpens
develop
new
medicin
order
approach
fulli
develop
exploit
unfortun
take
lot
persuas
best
way
persuad
power
provid
scientif
evid
effect
approach
problem
lie
support
evid
provid
order
provid
evid
must
first
supporteda
classic
catch
cost
medicin
play
modest
role
overal
cost
health
care
western
countri
capitalist
approach
health
care
alreadi
unfortun
result
exclus
larg
number
citizen
countri
interest
see
govern
deal
grow
problem
shift
focu
sustain
expens
health
care
system
start
investig
possibl
method
improv
health
citizen
reduc
cost
even
mean
use
inexpens
medicin
plant
chapter
use
annua
exampl
quick
potenti
lead
found
use
revers
pharmacolog
approach
scientif
investig
medicin
properti
remark
plant
unfortun
limit
reason
state
howev
know
plant
use
hundr
year
treatment
variou
ailment
without
report
seriou
side
effect
toxic
plant
current
use
treatment
malaria
approv
hiv
ethnobotan
use
also
report
peopl
start
use
annua
treatment
variou
form
cancer
anam
lui
et
al
recent
shown
artemisinin
inde
show
select
action
breast
cancer
cell
line
select
enough
reason
studi
plant
detail
conclud
develop
new
drug
prohibit
expens
mani
lead
compound
fail
clinic
trial
annua
uncontrol
clinic
trial
happen
exactli
right
placein
countri
suffer
burden
hiv
therefor
import
put
health
shortterm
profit
lead
longterm
profit
therefor
call
perform
indepth
scientif
studi
tradit
formul
consist
annua
treatment
hiv
malaria
also
certain
form
cancer
medicin
plant
definit
potenti
global
impact
approach
health
care
importantli
also
honest
scientif
scrutini
annua
might
turn
work
way
expectonli
time
tell
